Shares of Ampio Pharmaceuticals Inc. (AMPE) cratered on Monday as a multi-center study, dubbed STRIDE, evaluating intra-articular injections of Ampion in patients with severe osteoarthritis of the knee did not reach its primary endpoint against the saline control.